The US government will stop distributing free doses of Merck & Co’s COVID-19 antiviral treatment molnupiravir by the middle of next month and expects it to be sold on the commercial market instead. The Administration for Strategic Preparedness and Response, a division of the U.S. Department of Health and Human Services, said it expects the drug to enter traditional commercial distribution in November.